Olman Elizondo’s Post

💡 Want to learn more about AMR? Check out RaDAR's new animated series🎬 It explains the #AMR challenge and how #innovation through #PPI is key to tackling it. 🌍

A quick reminder about ISPOR Europe 2024!! Medalis Ltd will be presenting a poster at ISPOR Europe 2024 on November 19th, 2024 in Barcelona! Our poster, titled: “Evaluating the Economic Impact of Real-World Costs in nAMD Treatment Using Neutral Theory: A UK Perspective,” dives deep into the economic costs nAMD clinics face. Our findings revealed the importance of non-drug costs and clinic strain impacts which are often overlooked in traditional cost-effectiveness assessments. If you're interested in real-world evidence and health economics, and how these are shaping the treatment landscape for nAMD, we ask you to join us and explore our findings firsthand! To book a meeting with us please scan the QR code below and select a slot on the 19th of November. Looking forward to insightful discussions and sharing our research with the wider ISPOR community. See you there! #ISPOREurope2024 #nAMD #HealthEconomics #MedalisLtd #CostEffectiveness #ResearchInnovation

📢 Exciting Collaboration Announcement❗ We are thrilled to announce the start of a successful partnership between Laboratoires KÔL and BlueDil International! KOL Laboratoires, a French start-up with a global vision, is dedicated to addressing unmet medical needs in #ophthalmology, with a special focus on rare corneal diseases. KOL Laboratoires is committed to bring innovative solutions fitting patients’ needs and BlueDil International is proud to be a trusted #partner in their market expansion. Our support started in Spain and Germany, and we will extend our efforts to Switzerland and Italy in the coming year. Together, we are committed to making a meaningful impact on the rare disease space and driving forward innovation in #corneal care. Looking forward to a successful journey ahead! 🌍 💻Visit our website to discover how we partner 👉 https://lnkd.in/dYd3hCC6 #RareDiseases #CornealPathologies #Innovation #OrphanDrugs 

For more information on this Oral Abstract where GOG-0724 will be presented during the 2024 ASCO Annual Meeting, go to https://ow.ly/3NML50RUlVV or click in bio. #clinicaltrials #GOGF #GOGPartners #GynecologicOncology #ASCO24

Recently, our Microbio team, Field Application Scientist Judith Lucke and Medical Science Liaison Katie Shepherd joined our Portuguese distributor Iberlab - soluções para laboratórios, lda and their customer, Dr. Sandra Rebelo at Centro Hospitalar Universitário de São João. Together with Dr Rebelo’s fantastic team, they supported the hospital's first run of the InfectID™-BSI assay. The team identified pathogens in three sepsis patients, providing potentially life-saving insights for their ongoing care. One of the results was later confirmed by a sputum sample, aligning with the InfectID™-BSI findings—nine days after the assay had delivered its result. The significance of this finding underscores the power of InfectID™-BSI in improving sepsis outcomes. This marks the beginning of an exciting collaboration with a team equally committed to advancing patient care through faster, targeted pathogen identification allowing to drastically speed up targeted treatment. Dr. Sandra Rebelo shared, "Big things start small, and we expect to give bigger steps towards a solution that would improve the clinical approach for our patients. No man is an island, so teamwork is absolutely precious in addressing clinical issues. All together for the same purpose". #SepsisAwareness #RapidDiagnostics #InfectIDBSI #MicrobioCollaboration João Pedro Carvalho Teixeira

The team at AZAFAROS B.V. is excited to announce positive topline data from our Phase 2 RAINBOW study (NCT05758922 https://lnkd.in/eSew9JZH) investigating our lead asset, #nizubaglustat, in patients with #GM2 gangliosidosis and Niemann-Pick disease type C (#NPC). The study’s primary endpoint was met, confirming the safety profile of nizubaglustat, and the study aim of determining the safety, pharmacodynamics, and pharmacokinetics of two different treatment doses was achieved. Stefano Portolano, MD, CEO at Azafaros, said: “𝑇ℎ𝑒 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑃ℎ𝑎𝑠𝑒 2 𝑅𝐴𝐼𝑁𝐵𝑂𝑊 𝑠𝑡𝑢𝑑𝑦 𝑚𝑎𝑟𝑘 𝑎 𝑝𝑖𝑣𝑜𝑡𝑎𝑙 𝑚𝑜𝑚𝑒𝑛𝑡 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑒𝑣𝑒𝑙𝑜𝑝𝑚𝑒𝑛𝑡 𝑜𝑓 𝑛𝑖𝑧𝑢𝑏𝑎𝑔𝑙𝑢𝑠𝑡𝑎𝑡. 𝑇ℎ𝑒 𝑑𝑢𝑎𝑙 𝑚𝑜𝑑𝑒 𝑜𝑓 𝑎𝑐𝑡𝑖𝑜𝑛 𝑠𝑒𝑡𝑠 𝑛𝑖𝑧𝑢𝑏𝑎𝑔𝑙𝑢𝑠𝑡𝑎𝑡 𝑎𝑝𝑎𝑟𝑡 𝑎𝑠 𝑎 𝑙𝑒𝑎𝑝 𝑓𝑜𝑟𝑤𝑎𝑟𝑑 𝑓𝑟𝑜𝑚 𝑜𝑡ℎ𝑒𝑟 𝑎𝑔𝑒𝑛𝑡𝑠. “𝑊𝑒 𝑎𝑟𝑒 𝑒𝑥𝑐𝑖𝑡𝑒𝑑 𝑏𝑦 𝑡ℎ𝑒 𝑟𝑒𝑠𝑢𝑙𝑡𝑠 𝑜𝑓 𝑡ℎ𝑒 𝑠𝑡𝑢𝑑𝑦 𝑎𝑛𝑑 𝑚𝑜𝑟𝑒 𝑡ℎ𝑎𝑛 𝑐𝑜𝑛𝑓𝑖𝑑𝑒𝑛𝑡 𝑡ℎ𝑎𝑡 𝑛𝑖𝑧𝑢𝑏𝑎𝑔𝑙𝑢𝑠𝑡𝑎𝑡 ℎ𝑎𝑠 𝑡ℎ𝑒 𝑝𝑜𝑡𝑒𝑛𝑡𝑖𝑎𝑙 𝑡𝑜 𝑏𝑒𝑐𝑜𝑚𝑒 𝑎 𝑐𝑜𝑛𝑣𝑒𝑛𝑖𝑒𝑛𝑡, 𝑙𝑖𝑓𝑒-𝑐ℎ𝑎𝑛𝑔𝑖𝑛𝑔 𝑡ℎ𝑒𝑟𝑎𝑝𝑦 𝑓𝑜𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑎𝑓𝑓𝑒𝑐𝑡𝑒𝑑 𝑏𝑦 𝐺𝑀1 𝑎𝑛𝑑 𝐺𝑀2 𝑔𝑎𝑛𝑔𝑙𝑖𝑜𝑠𝑖𝑑𝑜𝑠𝑒𝑠 𝑎𝑛𝑑 𝑁𝑃𝐶. 𝐴𝑧𝑎𝑓𝑎𝑟𝑜𝑠 𝑖𝑠 𝑡ℎ𝑎𝑛𝑘𝑓𝑢𝑙 𝑡𝑜 𝑡ℎ𝑒 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠 𝑎𝑛𝑑 𝑡ℎ𝑒𝑖𝑟 𝑓𝑎𝑚𝑖𝑙𝑖𝑒𝑠 𝑓𝑜𝑟 𝑡ℎ𝑒𝑖𝑟 𝑖𝑚𝑝𝑜𝑟𝑡𝑎𝑛𝑡 𝑐𝑜𝑛𝑡𝑟𝑖𝑏𝑢𝑡𝑖𝑜𝑛 𝑡𝑜 𝑡ℎ𝑒 𝑅𝐴𝐼𝑁𝐵𝑂𝑊 𝑠𝑡𝑢𝑑𝑦. 𝐴𝑧𝑎𝑓𝑎𝑟𝑜𝑠 𝑖𝑠 𝑛𝑜𝑤 𝑝𝑜𝑖𝑠𝑒𝑑 𝑡𝑜 𝑒𝑚𝑏𝑎𝑟𝑘 𝑜𝑛 𝑎 𝑔𝑙𝑜𝑏𝑎𝑙 𝑃ℎ𝑎𝑠𝑒 3 𝑡𝑟𝑖𝑎𝑙 𝑛𝑒𝑥𝑡 𝑦𝑒𝑎𝑟.” The data will be presented at the #SSIEM2024 Annual Symposium, to be held 3-6 September in Porto, Portugal. Read the full story here: https://lnkd.in/ei4aUTZj #rarediseases, #clinicaltrials, #research, #azafaros, #NPC, #GM1, #GM2, #RAINBOW

‼️‼️‼️No surprises here Truveta research and collaborators winning #ISPOR general poster of the year 🎉🎉🔥 #rwe #rwd #realworldevidence #realworlddata #diabetesresearch #clinicaldata #ehrdata #patientoutcomes #A1ctrends

#eucrof25: Historical control data in clinical trials, very interesting! I will listen in to this presentation by Atiye Nazari from Nestlé Research & Development

AAGL 2024, 53rd Global Congress on MIGS. Tune into the Rythm of Innovation. Enhance your surgical expertise, network with leaders, and enojoy the soulful sounds of the big easy. Register today by clicking the link below. https://lnkd.in/dbYF3t_w #AAGL2024 #ISFGS #AAGL #fluorescence #ICG #FGS #MIGS #fluorescenceimaging Joao Paulo Epprecht

Later this week our team is headed to the #FLORetina in Florence, Italy, where we’ll present 52-week data from our LUNA Phase 2 trial of Ixo-vec. Ixo-vec is our single-injection #genetherapy candidate for treatment of patients with #wetAMD. Learn more: https://bit.ly/3UTE24c